Double Bond Pharmaceutical (DBP) Q1 2026 earnings summary

Executive summary

• Completed a large-scale Real-World Evidence study for Temodex, showing significant survival benefits over standard treatment in malignant brain tumors.

• Strategic focus on licensing agreements and regaining control of key portfolio assets, including initiating legal action to reclaim iron succinate rights.

• Four parallel partnership discussions underway to maximize commercial value.

Financial highlights

• Total revenue for Q1 2026 was 0.1 MSEK, up from 0.0 MSEK year-over-year.

• Operating loss improved to -0.3 MSEK from -0.4 MSEK year-over-year.

• Net loss narrowed to -0.3 MSEK from -1.1 MSEK year-over-year.

• Earnings per share was 0.00, compared to -0.01 in Q1 2025.

Outlook and guidance

• Focus remains on securing licensing deals with prioritized partners and strengthening rights to other portfolio products.

• Ongoing efforts to publish Temodex study results and present at major scientific congresses to enhance commercial prospects.